Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 116 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Arthritis, Juvenile Clear all
Completed No phase listed Observational Accepts healthy volunteers

Juvenile Rheumatoid Arthritis Research Registry

NCT00090571
View directory record Official record
Conditions
Juvenile Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Sep 30, 2026, 6:03 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 30, 2026, 6:03 AM EDT
Completed Phase 1 Interventional

A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis

NCT05252533
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis, Psoriasis, Arthritis, Juvenile
Interventions
Ustekinumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Huntington Beach, California • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Sep 30, 2026, 6:03 AM EDT
Terminated Phase 4 Interventional Results available

Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis

NCT00637780
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
Sulfasalazine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 30, 2026, 6:03 AM EDT
Recruiting Phase 3 Interventional

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

NCT05609630
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Upadacitinib, Tocilizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
1 Year to 17 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Valhalla, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 30, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis

NCT00988221
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
10
States / cities
Hartford, Connecticut • Washington D.C., District of Columbia • Delray Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 30, 2026, 6:03 AM EDT
Completed No phase listed Observational

Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference

NCT02524340
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 19 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 30, 2026, 6:03 AM EDT
Recruiting No phase listed Observational

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

NCT04833465
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Fibromyalgia
Interventions
No Intervention
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
5 Years to 21 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Sep 30, 2026, 6:03 AM EDT
Terminated Phase 2 Interventional Results available

Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIA

NCT05710640
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
Active tcVNS, Sham tcVNS
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
San Francisco, California • Orlando, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 30, 2026, 6:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spine Quantitative Computed Tomography (QCT)

NCT00762879
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 21 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Sep 30, 2026, 6:03 AM EDT
Completed No phase listed Observational

Use of Thermal and 3D Imaging to Quantify Arthritis

NCT01044823
View directory record Official record
Conditions
Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis
Interventions
3D and thermal imaging
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
4 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 30, 2026, 6:03 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA

NCT00652925
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
Celecoxib, Naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 18 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
31
States / cities
San Diego, California • Hartford, Connecticut • Delray Beach, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated May 30, 2008 · Synced Sep 30, 2026, 6:03 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

NCT01455701
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 24 Months
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Sep 30, 2026, 6:03 AM EDT
Completed Not applicable Interventional

Fitness Integrative Training for Pediatric Rheumatology Disorders

NCT06556992
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus of Childhood, Joint Hypermobility, Juvenile Dermatomyositis
Interventions
FIT Teens
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 19 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 30, 2026, 6:03 AM EDT
Not listed Phase 3 Interventional

The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis

NCT00012506
View directory record Official record
Conditions
Uveitis, Arthritis, Juvenile Rheumatoid
Interventions
TNFR:Fc
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Sep 30, 2026, 6:03 AM EDT
Withdrawn Not applicable Interventional

Effects of Growth Hormone in Chronically Ill Children

NCT00286689
View directory record Official record
Conditions
Hurler Syndrome, Cerebral Palsy, Juvenile Rheumatoid Arthritis, Crohn Disease, HIV Infections
Interventions
Growth Hormone, Whole body Protein turnover, DEXA scan
Drug · Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Sep 30, 2026, 6:03 AM EDT
Completed No phase listed Observational

A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur

NCT03769558
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Months and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Sep 30, 2026, 6:03 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

NCT06751238
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis
Interventions
Secukinumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
Loma Linda, California • Gainesville, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 30, 2026, 6:03 AM EDT
Recruiting Phase 3 Interventional

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

NCT06654882
View directory record Official record
Conditions
Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
Interventions
TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab, Tofacitinib
Drug
Lead sponsor
Duke University
Other
Eligibility
2 Years to 21 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 6:03 AM EDT
Completed No phase listed Observational

Cost of Care for Juvenile Idiopathic Arthritis

NCT01469897
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Omaha, Nebraska • Cleveland, Ohio • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 30, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)

NCT00642460
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Placebo, Non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate, corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Hartford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Sep 30, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Results available

An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)

NCT02776735
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Sarilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 30, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Jointstrong Intervention for Juvenile Arthritis

NCT01166750
View directory record Official record
Conditions
Juvenile Arthritis
Interventions
CD-ROM, Wait-list Control Group
Behavioral
Lead sponsor
Michael Rapoff, Ph.D.
Other
Eligibility
8 Years to 12 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Sep 30, 2026, 6:03 AM EDT
Completed Phase 4 Interventional Results available

Adalimumab in JIA-associated Uveitis Stopping Trial

NCT03816397
View directory record Official record
Conditions
Uveitis, JIA
Interventions
Adalimumab, Placebo
Biological · Other
Lead sponsor
Nisha Acharya
Other
Eligibility
2 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Sep 30, 2026, 6:03 AM EDT